Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
20111.4k citationsA Gallacher, Stephen Hall et al.The Lancetprofile →
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial
2008652 citationsPaul Emery, Ferdinand C. Breedveld et al.The Lancetprofile →
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
2014598 citationsRoy Fleischmann, Stephen Hall et al.profile →
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
2008432 citationsMark C. Genovese, E. C. Hsia et al.Annals of the Rheumatic Diseasesprofile →
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
2013366 citationsZhanguo Li, Stephen Hall et al.Annals of Internal Medicineprofile →
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
2014341 citationsArthur Kavanaugh, Stephen Hall et al.Annals of the Rheumatic Diseasesprofile →
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
2018331 citationsMark C. Genovese, Roy Fleischmann et al.The Lancetprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Stephen Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Hall more than expected).
This network shows the impact of papers produced by Stephen Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Hall. The network helps show where Stephen Hall may publish in the future.
Co-authorship network of co-authors of Stephen Hall
This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Hall.
A scholar is included among the top collaborators of Stephen Hall based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Stephen Hall. Stephen Hall is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Kremer, Joel, Zhanguo Li, Stephen Hall, et al.. (2013). Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis. Annals of Internal Medicine.5 indexed citations
McKnight, Stafford, et al.. (2008). The use of low-toxic heavy suspensions in mineral sands evaluation and zircon fractionation. FedUni ResearchOnline (Federation University Australia). 108(1). 25–33.7 indexed citations
11.
Emery, Paul, Ferdinand C. Breedveld, Stephen Hall, et al.. (2008). Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. The Lancet. 372(9636). 375–382.652 indexed citations breakdown →
12.
Kay, Jonathan, Patrick Durez, Eric L. Matteson, et al.. (2007). Improvement in DAS28 response through one-year of golimumab treatment in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo controlled, dose ranging trial. Annals of the Rheumatic Diseases. 66. 175–176.2 indexed citations
13.
Emery, Paul, Patrick Durez, Ferdinand C. Breedveld, et al.. (2007). Remission rates in subjects with active early rheumatoid arthritis 1 year results of the COMET trial: Combination of methotrexate and etanercept in active early rheumatoid arthritis. DIAL (Catholic University of Leuven). 56(12). 4310–4311.5 indexed citations
14.
Kay, Jonathan, Patrick Durez, Eric L. Matteson, et al.. (2006). One-year results of golimumab compared with placebo in patients with active RA despite treatment with methotrexate: A phase II, randomized, double-blind, placebo-controlled, dose-ranging trial.. Digital Access to Libraries. 54(9).7 indexed citations
15.
Kay, Jonathan, Patrick Durez, E. L. Matteson, et al.. (2005). Subcutaneous injection of CNTO 148 compared with placebo in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, dose-ranging trial.. Digital Access to Libraries. 52(9).1 indexed citations
16.
Green, Sally, Rachelle Buchbinder, L Barnsley, et al.. (2002). Acupuncture for lateral elbow pain (Cochrane Review). 4. 1–12.18 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.